Nov 25, 2024
Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support the advancement of...
Oct 29, 2024
Copenhagen, Denmark, October 29th, 2024 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, today announces that its CEO, Michael Pehl will join fellow...
Oct 8, 2024
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple STS subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety,...
Aug 20, 2024
August 20th, 2024, Copenhagen, Denmark and Shanghai, China — Adcendo ApS (“Adcendo”) and Multitude Therapeutics Inc. (“Multitude”) jointly announced today that they have signed a licensing agreement for the development of a novel, highly differentiated...
May 29, 2024
Raises additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors Funds will be used to further strengthen growing pipeline of first in class ADC assets, including lead asset targeting uPARAP Iyona Rajkomar,...
Apr 4, 2024
Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patients uPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma...
